Spelling suggestions: "subject:"umbilical core blood"" "subject:"umbilical cold blood""
41 |
Experiência de enfermeiras que atuam na coleta de células-tronco de sangue de cordão umbilical / Experience of nurses who work in the collection of stem-cells from umbilical cord bloodEny Dórea Paiva 13 December 2007 (has links)
A coleta de sangue de cordão umbilical e placentário (SCUP) é uma atividade delegada ao enfermeiro, abrindo um novo campo de atuação para esse profissional que se configura em um novo processo de trabalho e na inserção de mais um procedimento no contexto da assistência obstétrica. O objetivo deste estudo foi compreender a vivência de enfermeiras no exercício da atividade de coleta de amostras de SCUP para armazenamento de células progenitoras hematopoiéticas. Trata-se de um estudo descritivo com abordagem metodológica qualitativa. Os referenciais teórico e metodológico adotados neste estudo foram o Interacionismo Simbólico e a Teoria Fundamentada nos Dados. Participaram do estudo nove enfermeiras que atuam na atividade de coleta de SCUP para bancos de sangue de privados e públicos. Os dados foram obtidos por meio de entrevistas que foram gravadas e transcritas. A experiência da enfermeira que exerce a atividade de coleta de SCUP é compreendida pelas categorias: ACEITANDO A PROPOSTA DE TRABALHO, TENDO ATRIBUIÇÕES A CUMPRIR, PREPARANDO-SE PARA PROCEDER A COLETA DE SCUP, ENCONTRANDO CONDIÇÕES FAVORÁVEIS PARA REALIZAR A COLETA DE SCUP, UTILIZANDO ESTRATÉGIAS PARA GARANTIR A COLETA DE SCUP, ENCONTRANDO CONDIÇÕES DESFAVORÁVEIS PARA REALIZAR A COLETA DE SCUP, PROCEDENDO À COLETA DE SCUP, CONCLUINDO A COLETA DE SCUP e AVALIANDO O TRABALHO REALIZADO. Trabalhar como um profissional tendo de se inserir em um contexto desconhecido com profissionais que atuam em equipe nas diversas maternidades, coloca a enfermeira coletadora frente a situações que exigem rápida adaptação para que realize a coleta de SCUP, atendendo todas as recomendações exigidas para a coleta desse material. Um dos aspectos evidenciados e merecedor de destaque é o fato da enfermeira coletadora deparar-se com dificuldades referentes ao relacionamento com a equipe que presta assistência obstétrica; esta necessita compreender e incorporar em seu processo de trabalho no contexto da assistência ao parto que a enfermeira coletadora de SCUP presta serviço ao BSCUP público ou privado. Apesar das dificuldades relatadas pelas enfermeiras coletadoras no desenvolvimento de sua atividade, percebe-se que elas se encontram motivadas a continuar atuando nesse novo campo, seja pela remuneração, seja pela percepção de estar realizando uma atividade que beneficiará o tratamento de doenças. Vale ressaltar que este estudo poderá ajudar aos profissionais envolvidos no contexto do parto e nascimento a entenderem a atividade de coleta e a compreenderem que a equipe multiprofissional deve atuar em prol de um objetivo comum, além de serem informados a respeito do potencial que as células-tronco vêm mostrando no tratamento de doenças hematológicas / The umbilical cord blood (UCB) collection is an activity delegated to the nurse, opening a new field of action for this professional who is set on a new process of work and the insertion of a further procedure in the context of obstetrical care. The objective of this study was to understand the experience of nurses in the exercise of the activity of collecting samples of UCB for storage hematopoietic progenitor cells. This is a descriptive study with qualitative approach. The benchmarks theoretical and methodological used in this study were the Interacionism Symbolic and Grounded Theory. Were involved in the study nine nurses who serve in the activity of UCB collection for blood banks, on private and public institutions. The data were obtained through interviews that were recorded and transcribed. The experience of the nurse who carries out the activity of UCB collection is understood by the categories: ACCEPTING THE WORK PROPOSAL, HAVING TASKS TO DELIVER, PREPARING TO PROCEDER THE UCB COLLECTION, FACING FAVOURABLE CONDITIONS TO PROCEDURE THE UCB COLLECTION, USING STRATEGIES TO ASSURE THE UCB COLLECTION, FACING UNFAVOURABLE CONDITIONS TO PROCEDURE THE UCB COLLECTION, DOING THE UCB COLLECTION PROCEDURE, FINALIZING THE UCB COLLECTION PROCEDURE and UNALIZING THE WORK CARRIED. Working as a professional who needs to take part into an unknown context with other professionals who works together in various maternity, puts the nurse through situations that require quick adaptation to develop the UCB collection, attending all the recommendations required for the material collection. One of the aspects highlighted and worthy of note is the fact the nurse encounter themselves with difficulties relating to the relationship with the team that provides obstetrical care, which needs to understand and incorporate in the process of work in the context of assistance for delivery that the nurse provides service to coord bank. Despite the difficulties reported by nurses who develop this activity, is known that they are motivated to continue working in this new field, by the remuneration or by the perception of performing an activity that will benefit the treatment of diseases. This study may help the professionals involved in the obstetrical care to understand the activity of UCB collection and that the multiprofessional team should work towards a common goal, besides being informed about the potential that stem cells come showing in the treatment of hematological diseases
|
42 |
Avaliação da viabilidade financeira do banco do sangue de cordão umbilical do Hemocentro de Ribeirão Preto / Evaluation of financial viability of the umbilical cord blood bank of the Hemocentro de Ribeirão PretoAna Paula Rocha Diniz Zanelli 02 March 2017 (has links)
Introdução. As células progenitoras hematopoéticas (CPH) têm sido utilizadas no tratamento de algumas doenças malignas hematológicas e de desordens hematopoéticas. Dentre estas células estão as CPHs provenientes de cordão umbilical e placentário (SCUP). Para coleta e armazenamento destas células foram criados os Bancos de Sangue de Cordão Umbilical e Placentário (BSCUP). No Brasil existe a rede BrasilCord e o BSCUP do Hemocentro de Ribeirão Preto é um dos que compõem esta rede. Objetivo. Avaliar a viabilidade financeira de um banco de sangue de cordão umbilical e placentário público comparando os custos de seus procedimentos com os valores ressarcidos definidos pela tabela SUS. Metodologia: Este estudo utilizou a metodologia de Custeio Baseado em Atividades (Activity-Based Costing - ABC), que procura reduzir as distorções provocadas pelo rateio arbitrário dos custos indiretos utilizando direcionadores de custos. Foram avaliados os custos diretos e indiretos da coleta, transporte, processamento, testagem e criopreservação de CPH proveniente de SCUP no primeiro semestre de 2015. Para os custos indiretos foram definidos os direcionadores de custo. Resultados Os resultados mostram que o BSCUP do Hemocentro de Ribeirão Preto foi deficitário no primeiro semestre de 2015. O déficit apurado por unidade foi de R$1.155,69 para o processamento semiautomatizado e R$1.703,78 para o processamento automatizado. O déficit total no período foi de R$ 100.376,50 quando 50 unidades foram processadas utilizando o método semiautomatizado e 25 pelo método automatizado. Conclusão. O valor ressarcido pelo SUS não cobre os gastos do BSCUP do Hemocentro de Ribeirão Preto. Isso pode ser atribuído a várias causas como: sistemática de pagamento pelo SUS apenas pelo produto criopreservado, elevados índices de rejeição das doadoras na maternidade e de descarte das unidades coletadas, embora este último seja menor que o descrito na literatura, e o custo do armazenamento em longo prazo. Os custos do BSCUP são menores que os descritos na literatura e poderiam ser reduzidos com melhorias de processos de gestão e aumento do número de unidades criopreservadas, bem como, por meio de descentralização de coletas para processamento centralizado. / Introduction. Hematopoietic progenitor cells (HPC) are being used in some hematologic malignancies and hematopoietic disorders treatment. Among these cells are the HPCs from umbilical blood cord (UCB). Umbilical cord blood banks were created to collect and store these cells. In Brazil there is a net called Brasilcord and the umbilical cord blood bank (UCBB)of the Hemocentro de Ribeirão Preto belongs to this net. Objective. To evaluate the financial viability of a public umbilical cord blood bank and compare the costs from its procedure with the values reimbursed defined by the SUS table. Methodology.This study used the ActivityBased Costing, which tries to reduce distortions caused by arbitrary apportionment of indirect costs using cost drivers. Direct and indirect costs of collection, transport, processing, testing and cryopreservation of HPCs from umbilical cord blood were evaluated. Cost drivers were defined for indirect costs. Results. The results showed that there was a deficit in the UCBB of the Hemocentro de Ribeirão Preto in the first semester of 2015. The deficit was R$1.155,69 when the unit was processed by the semi-automated method and R$1.703,78 when it was processed by an automated method. The total deficit in the period was R$100.376,50 as 50 units were processed by a semi-automated method and 25 by an automated method. Conclusion. The amount reimbursed by SUS does not cover the UCBB of Hemocentro de Ribeirão Preto expenses. This can be attributed to several causes such as: systematic of reimbursement used by SUS that only cryopreserved units are payed, high percentage of deferral in the maternity and of discard of collected units, although this latter is smaller than that described in the literature and the cost of storage of the units for long periods. The costs of UCBB are lower than that described in the literature and could be reduced with improvements in managing process and increase the number of cryopreserved units as well as decentralization of collections for centralizes processing.
|
43 |
Caracterização morfológica de células-tronco mesenquimais de sangue umbilical e de tecido adiposo coletado por via intraabdominal e uterina em ovinos / Morphologic characterization of mesenchymal stem cells from umbilical cord blood and adipose tissue collected trough intraabdominal and uterine in sheepLeandro Fadel 29 June 2009 (has links)
As células-tronco mesenquimais (MSCs) são células estromais não-hematopoiéticas que possuem capacidade de diferenciação, sendo capazes, de diferenciar em diversos tecidos. As MSCs residem em vários tecidos vêm sido isoladas de diferentes tecidos, tais como cartilagem, tendão, tecido adiposo, do vaso e sangue umbilical, além de tecidos fetais . O isolamento e caracterização das populações mesenquimais no modelo ovino se faz importante, visto que ele é usado em ensaios pré-clínicos ortopédicos . Nesse estudo foram utilizados 5 amostras de sangue de cordão umbilical e 5 amostras de tecido adiposo peri-renal, provenientes de 10 ovinos fêmeas adultas. As coletas foram realizadas através de cirurgia para que o material coletado fosse o mais asséptico possível. Essas amostras foram submetidas a diferentes protocolos de isolamento, com a finalidade de se testar o mais eficiente. Somente um protocolo de cada tecido mostrou-se eficiente no isolamento da MSCs, porém nenhuma dessas amostras manteve-se viável após a primeira passagem. / Mesenchymal stem cells (MSCs) are non hematopoietic stromal cells that are able to differentiate through several tissues . MCSs home in several tissues and are being isolated from different tissues, such cartilage, tendon, adipose tissue, vessels and umbilical blood, and also from fetal tissues . The isolation and characterization of mesenchymal cells in sheep are important, because it is used in orthopedic pre-clinical trials . In this study were used 5 samples of umbilical blood and 5 samples of perirenal adipose tissue from 10 female sheep. All the samples were obtained through surgery, to harvest aseptic samples. These samples were tested in different protocols to evaluate the more efficient. Just one protocol from each source showed significant results in isolation, although none of the samples survived trough the first passage.
|
44 |
Odlišné vlastnosti buněk pupečníkové krve novorozenců zdravých a alergických matek / Different characteristics of cord blood cells of newborns of healthy and allergic mothersVlasáková, Kateřina January 2017 (has links)
The prevalence of allergy is increasing and it is becoming a serious problem not on- ly in medicine, but also in social and economic terms. The most effective way to minimize the development of allergic diseases is preventive measures. In recent years, many studies have attempted to confirm or rebut the hypothesis that early administration of probiotic bacteria to newborns and pregnant women before birth could have preventive effects on the development of allergy. In the Czech Republic, the probiotic strain Escherichia coli O83:K24:H31 (EC O83), being registered with the State Health Institute for Drug Control under the name Colinfant Newborn, has long been used to prevent allergies and paediatri- cians have long been known and used it against various diarrhoea. The aim of this work was to elucidate the effect of EC O83 on CBMC (cord blood mononuclear cells) and to compare the ability of CBMC of healthy mothers (children with a relatively low risk of developing allergic disease) and allergic mothers (children at high risk of developing allergies) to form cytokines in response to EC O83 stimulation. Phytohemagglutinin was used as a positive control, Escherichia coli Nissle 1917 was used as a reference probiotic strain, which is much more known abroad than EC O83. Cytokine production was detected by...
|
45 |
Rozdílná schopnost in vitro vypěstovaných dendritických buněk dětí zdravých a alergických matek stimulovat imunitní odpověď / Different capacity of in vitro generated monocyte-derived dendritic cells of newborns of healthy and allergic mothers to prime immune responsesSúkeníková, Lenka January 2017 (has links)
(EN) Reduced microbial stimulation of an immature neonatal immune system can lead to a poor balance adjustment of immune responses, thus contributing to the development of allergic diseases, whose incidence continues to rise. One of the promising precautionary measures seems to be an early preventive administration of probiotic bacteria to pregnant or nursing mothers, or to newborns. Previous works have described a beneficial effect of Escherichia coli O83:K24:H31 (E. coli O83) in the prevention of allergic diseases. In order to contribute to the clarification of E. coli O83 effects on the neonatal immune system, its immune- modulating properties were tested in vitro on umbilical cord blood cells. The ability of E. coli O83 to support the maturation of in vitro-derived dendritic cells from cord blood precursors (moDCs) of the children of healthy (children with a relatively low risk of allergy) and allergic (children at a relatively high risk of developing allergies) mothers was tracked by flow cytometry, qPCR and ELISA. Probiotic bacteria-stimulated moDCs were subsequently cultured with autologous naive CD4+ T lymphocytes and immune response polarization was also characterised by flow cytometry, qPCR, and ELISA. It was evident from the results that E. coli O83 promoted moDCs maturation. The presence of...
|
46 |
Factors determining the composition of a public cord blood stem cell bank including HLA diversityMellet, Juanita January 2013 (has links)
The human leukocyte antigen (HLA) is the most polymorphic region in the human genome and accounts for more than 10% of human diversity. This region plays an important role in matching donors and recipients for transplantation. The South African Bone Marrow Registry (SABMR) does not reflect the demographics of the South African population. The large number of polymorphisms resulting from HLA diversity in the Black South African population and their limited representation in the SABMR reduce the chances of finding adequate matches between donors and recipients in this group. Umbilical cord blood is an alternative to bone marrow for the treatment of fatal diseases. Less strict HLA matching is required due to the naive nature of the T cells in cord blood. A public umbilical cord blood bank is a necessity in trying to cater for the diverse population in South Africa. However, the ethnic diversity of the South African population poses a great challenge in constituting a public umbilical cord blood bank that is representative of the entire population. The Roche designed next generation sequencing (NGS) high resolution (HR) HLA typing kit enables sequencing of additional HLA exons and could improve the degree of matching between individuals to ultimately decrease adverse reactions. An extensive study of the literature was performed to establish the demographics, linguistics, and HLA diversity of the South African population to determine how a public cord blood bank should be constituted. In addition, HLA genotyping was performed by 454 NGS on 20 samples that had previously been HLA typed by conventional methods. The 454 NGS technique made use of a Roche designed medium and high resolution HLA typing kit to genotype the samples. It was possible to assign accurate genotypes to 95.5% of the loci of interest for the total number of 20 samples using the MR kit, compared with 98.5% using the HR kit. In conclusion, the present study indicates the extreme HLA diversity in the South African population, and therefore, recommends constituting the first public umbilical cord blood bank in Gauteng on the basis of race or major ethnic groupings. A minimum number of 10 000 cord blood units is needed to initiate the bank. Furthermore, the 454 NGS platform together with the HR HLA typing kit display potential as an alternative method to be used in a public cord blood bank, as well as routine clinical and diagnostic laboratories, to ultimately improve HLA matching between donors and recipients. / Dissertation (MSc)--University of Pretoria, 2013. / gm2014 / Immunology / unrestricted
|
47 |
Investigation of a Novel Formulation from Umbilical Cord Blood Stem Cell-Derived Exosomes and Antioxidant (Selenium) in Malignant Melanoma CellsAltobalani, Tahera S.H.M. January 2023 (has links)
Introduction: Malignant Melanoma (MM), caused by UV radiation-induced DNA damage, is the most invasive form of skin cancer and has an increasing incidence worldwide. The hallmarks of MM include the presence of reactive oxygen species (ROS) and excessive proliferation of tumour cells. Many treatments are available or under investigation as anticancer therapeutics such as cell therapy, immunotherapy, gene therapy and nanotechnology-based strategies but they all have severe complications and side effects that limit their wider use.
Methods: The present in vitro study has evaluated the genotoxic and cytotoxic effects of Se and CBSC-derived exosomes, individually and in combination, on lymphocytes from MM patients and healthy controls, and on the CHL-1 melanoma cell line. The comet assay and cell counting kit-8 (CCK-8) assay were used to measure genotoxicity and cytotoxicity, respectively, in all cell types. Molecular mechanisms underlying the observed effects were explored using transcriptional and protein expression profiling of key cell cycle and apoptosis genes, by employing the RT qPCR and Western blotting techniques.
Conclusion: Selenium displays antioxidant and genoprotective effects in human lymphocytes, especially in MM patients. Both Se (10 μM) and CBSC-derived exosomes (120 μL) are well tolerated in lymphocytes, but show significant genotoxicity and cytotoxicity towards the CHL-1 cell line, with combined administration exhibiting a synergistic effect.
|
48 |
Nouvelles stratégies thérapeutiques des affections articulaires du cheval : évaluation du potentiel thérapeutique des chondrocytes autologues et des cellules souches de cordon ombilical (sang et gelée de Wharton) : vers l'industrialisation de cellules médicaments. / New therapeutic strategies for articular disorders in the equine model : therapeutic potential evaluation of autologous chondrocytes and umbilical cord stem cells (from umbilical cord blood and Wharton jelly) : toward industrialization of drug cellsRakic, Rodolphe 05 September 2017 (has links)
Les affections articulaires touchant le cartilage, telles que les lésions focales et l’arthrose, correspondent aux principales causes de baisse de performance et d’arrêt prématuré de la carrière sportive du cheval. Ainsi, le traitement des affections du cartilage représente un enjeu vétérinaire majeur dans le monde équin, du fait des importantes pertes financières qu’elles occasionnent à la filière. Les faibles capacités de réparation intrinsèque du cartilage, ainsi que l’absence de thérapie à long terme des dommages cartilagineux, nécessitent le recours à des thérapies de nouvelles générations telle que l’ingénierie tissulaire du cartilage. Dans ce cadre, notre étude s’est attachée à comparer différents types cellulaires pour la génération de cartilage in vitro, afin d’envisager une implantation pour traiter les atteintes cartilagineuses chez le cheval. Une technique initialement développée chez l’Homme, la transplantation de chondrocytes autologues, représente toujours un « gold standard » en ingénierie tissulaire du cartilage. Dans ce travail de thèse, après avoir développé une nouvelle génération de substitut cartilagineux de haute qualité biologique, à partir de chondrocytes articulaires équins, des limites techniques et biologiques inhérentes au type cellulaire persistent. Ainsi, nos travaux se sont tournés vers la recherche de types cellulaires alternatifs. Les cellules souches/stromales mésenchymateuses (CSM) néonatales issues de cordon ombilical telles que les CSM de sang placentaire (CSM-SPL) et les CSM de gelée de Wharton (CSM-GW) pourraient représenter un avantage thérapeutique du fait de leur isolement non-invasif, de leur forte prolifération cellulaire et de leur capacité de différenciation en chondrocyte. Il est néanmoins indispensable de définir le meilleur candidat thérapeutique, parmi ces deux sources cellulaires, pour l’obtention d’un substitut cartilagineux de qualité biologique optimale. Ces résultats de thèse ont montré d’importantes différences dans le processus de chondrogenèse de ces deux sources de CSM néonatales et plaident en faveur de l’utilisation des CSM-SPL dans le cadre d’une stratégie thérapeutique d’ingénierie tissulaire du cartilage équin. Ces travaux ont permis une meilleure compréhension de la biologie du chondrocyte et des CSM. De surcroît, ces travaux permettent d’envisager de futurs essais cliniques chez le cheval, afin de traiter les affections articulaires de ce modèle gros animal. / Articular cartilage disorders, such as focal defects and osteoarthritis, are the main causes of decreased performance or early retirement of sport- and racehorses. Thus, cartilage disorders represent a major veterinary issue in the equine industry, due to significant financial losses. Poor intrinsic cartilage repair properties and the absence of long- term therapy for cartilage defects lead to the development and use of new generation therapies such as autologous chondrocytes implantation. In this context, our study aimed to compare different cell types for the in vitro cartilage generation, in order to implant the biological substitute to treat cartilage defects in the horse. A therapeutic strategy initially developed in human medicine, the autologous chondrocytes transplantation, always represents a "gold standard" in cartilage tissue engineering. In the present study, after developing a new generation of cartilaginous substitute of high biological quality, composed of equine articular chondrocytes, technical and biological limits inherent to the cell type persist. Thus, we have used alternative cell types such as neonatal mesenchymal stem/stromal cells (MSCs) from umbilical cord, such as umbilical cord blood MSC (UCB-MSCs) and umbilical cord matrix or Wharton jelly MSCs (UCM- MSCs). These MSCs sources could represent a therapeutic advantage due to their non-invasive isolation, their high cell proliferation and their ability to differentiate into chondrocytes. Nevertheless, it is essential to define the best therapeutic candidate between these two MSCs sources, to obtain an optimal quality for the neocartilaginous substitute. Our data highlighted important differences in the chondrogenesis process of these two neonatal MSCs sources, allowing us to consider UCB-MSCs as the best therapeutic candidate for equine cartilage tissue engineering. This work allows a better understanding of the chondrocyte and MSCs biology. Moreover, this work leads the way to setting-up future clinical trials in the horse, in order to treat articular defects of this large animal model.
|
49 |
Étude de la reconstitution de l’immunité spécifique au cytomégalovirus et au virus de la varicelle suite à la transplantation de sang de cordon ombilicalSalem, Insaf 02 1900 (has links)
La transplantation de sang de cordon ombilical (TSCO) constitue un traitement de choix pour une multitude de pathologies hématologiques malignes et non malignes chez l’enfant et dans certains cas l’adulte. La TSCO est associée à certaines complications, dont une reconstitution immunitaire plus lente et une incidence élevée d’infections opportunistes, notamment celles reliées au cytomégalovirus (CMV) et au virus varicella-zoster (VZV). Dans le cadre de ce travail, nous nous sommes intéressés dans un premier temps à la caractérisation de la reconstitution immunitaire spécifique au CMV et au VZV. Nos résultats ont démontré que la reconstitution de l’immunité cellulaire ne requiert ni un statut séropositif pré-transplantation ni le développement de la maladie. De plus, des reconstitutions spontanées ont été détectées chez certains patients séronégatifs vis-à-vis du CMV ou du VZV. Outre le fait qu’elle se manifeste surtout à partir de 6 mois post-transplantation, ladite reconstitution mérite le qualificatif de « protectrice » en termes de réactivations virales et du développement de signes cliniques lorsqu’une fréquence de 150 cellules produisant l’IFN-γ/million est dépassée. Toutefois, moins de 5% des patients développent une réponse T anti-VZV et anti-CMV au cours 100 premiers jours suivant la TSCO. Il est donc possible que les lymphocytes CD8+ T provenant du SCO, comparativement à leurs homologues provenant de la moelle osseuse (MO), présentent un défaut de fonctionnalité, communément appelé « épuisement clonal ». La caractérisation du répertoire de récepteurs inhibiteurs exprimés par les cellules T CD8+ suivant la TSCO ou la transplantation de moelle osseuse (TMO) a révélé une augmentation significative de la fréquence des cellules exprimant PD-1 tôt suivant la transplantation. Cette population, caractérisée majoritairement par un phénotype effecteur-mémoire (EM), démontre une perte significative de la capacité proliférative et exprime moins d'IFN-γ, d'IL-2, de TNF-α et de CD107a. Une meilleure caractérisation de la reconstitution immunitaire après TSCO permettrait, d'une part de sélectionner des biomarqueurs en vue d’une meilleure gestion des patients à risques de développer des infections virales et/ou de rechuter, et d'autre part d'améliorer leur pronostic. / Umbilical cord blood transplantation (UCBT) is a treatment of choice for a variety of hematological malignancies and non-malignant diseases in children and, in some cases, in adults. UCBT is associated with a slower immune reconstitution and a high incidence of viral infections, especially related to cytomegalovirus (CMV) and the varicella-zoster virus (VZV). As part of this work, we aimed to assess the reconstitution of CMV and VZV-specific T cell responses. Neither pre-transplant serostatus nor disease development is required for development of T cell mediated immunity. Moreover, spontaneous reconstitution detected in some patients who were seronegative for CMV or VZV. Detected especially after 6 months post-transplant, antiviral responses are protective in terms of viral reactivation and development of clinical signs, when a frequency of 150 cells producing d'IFN-γ / million is achieved. However, less than 5% of patients develop an antiviral response during the first 100 following UCBT. Compared to their bone marrow (BM) counterparts, UCB CD8+ T lymphocytes may be functionally impaired, a state commonly called « clonal exhaustion ». Characterization of the inhibitory receptors repertoire expressed by CD8+ T cells following UCBT and BMT showed a significant increase in the frequency of cells expressing PD-1 early after transplantation. This population, mainly characterized by effector phenotype, showed a significant loss of proliferative capacity and produced less IFN-γ, IL-2, TNF-α and CD107a. An improved understanding of the CD8+ T cell compartment following UCBT, as well as biomarkers related to T cell exhaustion will decrease infection, transplant related mortality and correlate with better prognosis
|
50 |
Papel de Notch e NF-kB na regulação de fatores de transcrição durante a diferenciação in vitro de células T a partir de células progenitoras hematopoéticas CD34+ / Role of Notch and NF-kB in the regulation of transcription factors during in vitro differentiation of T cells from CD34+Schiavinato, Josiane Lilian dos Santos 01 April 2011 (has links)
Em estudos anteriores desenvolvidos por este grupo de pesquisa uma expressão mais elevada de alvos transcricionais e componentes da via NF-kB, bem como altos níveis de NOTCH1, foi identificada em células-tronco hematopoéticas (CTH) CD34+ de sangue de cordão umbilical (SCU) quando comparadas às CTH CD34+ de medula óssea (MO). Este grupo verificou ainda, por comparação das células CD34+ com as CD133+ (mais primitivas) que diversos fatores de transcrição (FT) envolvidos com o potencial de hemangioblasto, com a autorenovação das CTH, e com a diferenciação linfóide; como: RUNX1/AML1, GATA3, USF1, TAL1/SCL, HOXA9 e HOXB4 apresentaram-se mais expressos em células mais primitivas. A potencial participação das vias Notch e NF-kB na regulação destes FT tem importância conceitual e prática no entendimento da biologia das CTH, e dos processos envolvidos na diferenciação destas células. Com isto em vista, este projeto teve como objetivo, estudar o papel da via NF-kB e da via Notch na regulação destes FT. Para isso, um modelo experimental in vitro, de diferenciação de CTH CD34+ em linfócitos T, foi utilizado e a influência de fatores agonistas e inibidores farmacológicos destas vias, foram avaliados por citometria de fluxo e PCR em tempo real. Nossos resultados evidenciam o papel da via Notch na regulação transcricional de HOXB4 e GATA3 em células-tronco hematopoéticas CD34+ humanas, o que foi confirmado com base na expressão dos alvos diretos de Notch (HEY1 e HES1). Notamos ainda, que a expressão dos transcritos HES1, GATA3 e HOXB4 é prejudicada pela síntese protéica das CTH, uma vez que quando empregamos o prétratamento com a droga CHX há aumento da transcrição dos mesmos. Também podemos inferir que a ação do TNF- é positiva sobre esses transcritos, já que quando o utilizamos há elevação do nível de expressão desses transcritos, com exceção a HES1. Em relação ao cocultivo das CTH com as células estromais de camundongos, verificamos que apenas a linhagem OP9-DL1 detém a capacidade de promover a diferenciação celular T, e isso foi comprovado pelo surgimento de células comprometidas com a linhagem linfocítica T, através da presença dos marcadores de superfície específico CD7+ e CD1a+. Esses resultados auxiliarão na compreensão dos mecanismos moleculares de regulação transcricional envolvidos não apenas na diferenciação de linfócitos T, mas também na manutenção de um estado mais primitivo das CTH. Este conhecimento pode vir a contribuir com o desenvolvimento ou otimização de protocolos laboratoriais visando à expansão de CTH ou geração de células T para usos terapêuticos. / In previous studies by this research group a higher expression of transcriptional targets and components via NF-kB, as well as high levels of NOTCH1, was identified in hematopoietic stem cells (HSC) CD34 + cells from umbilical cord blood (UCB) compared to CD34 + hematopoietic stem cells from bone marrow (BM). This group also found, by comparing the CD34 + cells with CD133 + (more primitive) that several transcription factors (TF) involved in the potential of hemangioblast, with self-renewal of hematopoietic stem cells and to differentiated lymphocytic; as Runx1 / AML1, GATA3, USF1, TAL1/SCL, HOXB4 and HOXA9 were more expressed in more primitive cells. The potential involvement of Notch signaling pathways and NF-kB in the regulation of FT has conceptual and practical importance in understanding the biology of HSC, and the processes involved in differentiation of these cells. With this in mind, this project aimed to study the role of NF-kB pathway and Notch signaling in the regulation of FT. For this, an experimental model in vitro differentiation of CD34 + hematopoietic stem cells into T lymphocytes, was used and the influence of pharmacological agonists and inhibitors of these pathways were evaluated by flow cytometry and real-time PCR. Our results highlight the role of Notch signaling in the transcriptional regulation of GATA3 and HOXB4 in hematopoietic stem cells CD34 + human, which was confirmed based on the expression of direct targets of Notch (HES1 and HEY1). We also note that the expression of transcripts HES1, GATA3 and HOXB4 protein synthesis is hampered by the HSC, since when we use the pre-treatment with the drug there CHX increased transcription thereof. We can also infer that the action of TNF- is positive about these transcripts, since when we use it for raising the level of expression of these transcripts, except the HES1. In relation to the HSC coculture with stromal cells of mice, we found that only the line-DL1 Op9 has the ability to promote T cell differentiation, and this was evidenced by the appearance of cells committed to the T lymphocyte lineage, through the presence of specific surface markers CD7 + and CD1a +. These results will help understand the molecular mechanisms of transcriptional regulation involved not only in the differentiation of T lymphocytes, but also in maintaining a more primitive state of HSC. This knowledge may contribute to the development or optimization of laboratory protocols aimed at the expansion of HSC or generation of T cells for therapeutic use.
|
Page generated in 0.1374 seconds